Connection

Martin Siegemund to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Martin Siegemund has written about Antibodies, Monoclonal, Humanized.
Martin Siegemund
Connection Strength
0.012
Antibodies, Monoclonal, Humanized
  1. Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study. Swiss Med Wkly. 2021 08 02; 151:w20550.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.